Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Looking back on COVID in order to move forward

Giuseppe Curigliano • 28 May 2020
ASCO 2020
General
CCC19 TERAVOLT

Giuseppe Curigliano, MD, PhD, University of Milano, Milan, Italy, talks through the data from the CCC19 study which looked at the clinical impact of COVID-19 on patients with cancer, and the TERAVOLT study which looked at the impact of type of cancer therapy and COVID therapy on survival. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Giuseppe Curigliano

6:54
Key clinical trials investigating immunotherapy in HER2+ and HR+ breast cancer
Giuseppe Curigliano • 9 Dec 2021
2:49
PROCURE: Genomic signatures and adjuvant chemotherapy for breast cancer in Europe
Giuseppe Curigliano • 9 Dec 2021
2:52
Future research directions for breast cancer
Giuseppe Curigliano • 9 Dec 2021
1:51
Reflecting on the use of CDK4/6 inhibitors in HR+ breast cancer
Giuseppe Curigliano • 25 Mar 2021

Related Videos

0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
3:10
PALOMA: subcutaneous amivantamab in advanced solid tumors
Natasha Leighl • 17 Apr 2024
The content of VJOncology is intended for healthcare professionals